Accessing health outcome data on high-cost medicines in Australia.
Data on health outcomes resulting from the use of medicines provide important evidence of cost-effectiveness. Currently, clinical information on individual patients, collected by Medicare Australia to assess eligibility for subsidised treatment with high-cost medicines, is inaccessible for research. Comprehensive data on drug use and health outcomes should be made accessible, with appropriate regulation, so that the effectiveness, utility and appropriateness of our systems of access to medicines can be independently analysed. In the interests of continuous improvement in medical care and optimal use of limited resources, we strongly advocate the enhancement of Medicare Australia databases and liberalisation of arrangements for access to administrative and clinical data.
Lu
Christine Y
CY
Faculty of Medicine, Department of Clinical Pharmacology, University of New South Wales, Sydney, NSW. christine.lu@student.unsw.edu.au
Williams
Kenneth M
KM
Day
Richard O
RO
D001315:Australia; D003625:Data Collection / Q000379:methods; D016208:Databases, Factual; D016527:Drug Costs / Q000706:statistics & numerical data*; D004335:Drug and Narcotic Control / Q000379:methods*; D006297:Health Services Accessibility; D006801:Humans; D009313:National Health Programs; D017063:Outcome Assessment, Health Care / Q000379:methods*